Clinical Effectiveness of Liraglutide Across Body Mass Index in Patients with Type 2 Diabetes in the United States: A Retrospective Cohort Study

Advances in Therapy

Volumn 31, Issue 9, 2014, Pages 986-999

  Chitnis, Abhishek S ^a   Ganz, Michael L ^a   Benjamin, Nicole ^a   Langer, Jakob ^b   Hammer, Mette ^b  

^a EVIDERA   (United States)

^b NOVO NORDISK INC   (United States)

Author keywords

Body mass index; Clinical effectiveness; Glycated hemoglobin; Liraglutide; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; LIRAGLUTIDE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; BODY MASS; COHORT ANALYSIS; DIABETIC PATIENT; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GOAL ATTAINMENT; HUMAN; HYPOGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; UNITED STATES; WEIGHT REDUCTION; ADOLESCENT; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84919839635     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-014-0153-5     Document Type: Article

References (27)

1. Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014. Atlanta: US Department of Health and Human Services; 2014.
2. National Diabetes Information Clearinghouse (NDIC). National Diabetes Statistics, 2011. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda; 2011. http://diabetes.niddk.nih.gov/DM/PUBS/statistics/. Accessed December 2013.
3. American Diabetes Association (ADA). The Cost of Diabetes, 2012. American Diabetes Association, Alexandria; 2013. http://www.diabetes.org/advocacy/news-events/cost-of-diabetes.html. Accessed December 2014.
4. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39–47. doi:10.1016/S0140-6736(09)60659-0.
5. DeVries JH, Bain SC, Rodbard HW, Seufert J, D’Alessio D, Thomsen AB, et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care. 2012;35(7):1446–54. doi:10.2337/dc11-1928.
6. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473–81. doi:10.1016/S0140-6736(08)61246-5.
7. Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(3):268–78. doi:10.1111/j.1464-5491.2009.02666.x.
8. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84–90. doi:10.2337/dc08-1355.
9. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375(9724):1447–56. doi:10.1016/S0140-6736(10)60307-8.
10. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia. 2009;52(10):2046–55. doi:10.1007/s00125-009-1472-y.
11. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care. 2009;32(7):1224–30. doi:10.2337/dc08-2124.
12. Suzuki D, Toyoda M, Kimura M, Miyauchi M, Yamamoto N, Sato H, et al. Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus. Intern Med. 2013;52(10):1029–34.
13. Niswender K, Pi-Sunyer X, Buse J, Jensen KH, Toft AD, Russell-Jones D, et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab. 2013;15(1):42–54. doi:10.1111/j.1463-1326.2012.01673.x.
14. Bailey T. Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm. Am J Med. 2013;126(9 Suppl 1):S10–20. doi:10.1016/j.amjmed.2013.06.009.
15. Fadini GP, Simioni N, Frison V, Dal Pos M, Bettio M, Rocchini P, et al. Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients. Acta Diabetol. 2013;50(6):943–9. doi:10.1007/s00592-013-0489-3.
16. Katout M, Zhu H, Rutsky J, Shah P, Brook RD, Zhong J, et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am J Hypertens. 2014;27(1):130–9. doi:10.1093/ajh/hpt196.
17. Kesavadev J, Shankar A, Krishnan G, Jothydev S. Liraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting. Int J Gen Med. 2012;5:317–22. doi:10.2147/ijgm.s27886.
18. Mulligan CM, Harper R, Harding J, McIlwaine W, Petruckevitch A, McLaughlin DM. A retrospective audit of type 2 diabetes patients prescribed liraglutide in real-life clinical practice. Diabetes Ther. 2013;4(1):147–51. doi:10.1007/s13300-013-0025-z.
19. Elkhenini H, New JP, Summers LK, Syed AA. Liraglutide therapy in obese people with type 2 diabetes—experience of a weight management centre. Eur J Intern Med. 2014;. doi:10.1016/j.ejim.2013.12.009.
20. Brixner DI, McAdam-Marx C, Ye X, Boye KS, Nielsen LL, Wintle M, et al. Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes Obes Metab. 2009;11(12):1122–30. doi:10.1111/j.1463-1326.2009.01081.x.
21. American Diabetes A. Standards of medical care in diabetes–2014. Diabetes Care. 2014;37(Suppl 1):S14–80. doi:10.2337/dc14-S014.
22. Young BA, Lin E, Von Korff M, Simon G, Ciechanowski P, Ludman EJ, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care. 2008;14(1):15–23.
23. Ginde AA, Blanc PG, Lieberman RM, Camargo CA Jr. Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr Disord. 2008;8:4. doi:10.1186/1472-6823-8-4.
24. Elliott MB, Schafers SJ, McGill JB, Tobin GS. Prediction and prevention of treatment-related inpatient hypoglycemia. J Diabetes Sci Technol. 2012;6(2):302–9.
25. Zinman B, Schmidt WE, Moses A, Lund N, Gough S. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab. 2012;14(1):77–82. doi:10.1111/j.1463-1326.2011.01493.x.
26. Ryder REJ, Sen Gupta P, Thong KY, ABCD Nationwide Liraglutide Audit Contributors. Liraglutide is effective across a range of obese body mass indices; findings from the Association of British Clinical Diabetologists (ABCD) nationwide liraglutide audit. Poster 801. Abstract available at http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2978&sKey=92a4dee8-8b53-4c91-a416-f9b6a9f63306&cKey=46c8beac-fa07-4f65-ac90-48aaa2b0b1ea&mKey=2dbfcaf7-1539-42d5-8dda-0a94abb089e8. 48th European Association for the Study of Diabetes (EASD) Meeting; October 1–5, 2012; Berlin, Germany.
27. Bode BW, Brett J, Falahati A, Pratley RE. Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies. Am J Geriatr Pharmacother. 2011;9(6):423–33. doi:10.1016/j.amjopharm.2011.09.007.